Saniona AB (ST:SANION) — Market Cap & Net Worth
Market Cap & Net Worth: Saniona AB (SANION)
Saniona AB (ST:SANION) has a market capitalization of $148.54 Million (Skr1.38 Billion) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #17784 globally and #303 in its home market, demonstrating a -6.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Saniona AB's stock price Skr10.00 by its total outstanding shares 138030134 (138.03 Million). Also see SANION total asset value for a full breakdown of the balance sheet.
Saniona AB Market Cap History: 2015 to 2026
Saniona AB's market capitalization history from 2015 to 2026. Data shows change from $234.05 Million to $148.54 Million (-1.48% CAGR). Also see SANION cash flow conversion for how efficiently the company converts equity into cash flow.
Saniona AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Saniona AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SANION stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.72x
Saniona AB's market cap is 0.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.11x
Saniona AB's market cap is 1.11 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $592.34 Million | $74.92 Million | $2.22 Million | 7.91x | 267.18x |
| 2017 | $443.53 Million | $20.69 Million | -$49.19 Million | 21.43x | N/A |
| 2018 | $462.31 Million | $54.88 Million | -$41.06 Million | 8.42x | N/A |
| 2019 | $381.75 Million | $2.66 Million | -$75.79 Million | 143.62x | N/A |
| 2020 | $306.00 Million | $8.20 Million | -$73.43 Million | 37.33x | N/A |
| 2021 | $131.46 Million | $10.48 Million | -$410.90 Million | 12.55x | N/A |
| 2022 | $45.53 Million | $15.28 Million | -$245.36 Million | 2.98x | N/A |
| 2023 | $59.57 Million | $16.84 Million | -$95.81 Million | 3.54x | N/A |
| 2024 | $119.43 Million | $334.67 Million | $188.71 Million | 0.36x | 0.63x |
| 2025 | $314.91 Million | $434.40 Million | $284.67 Million | 0.72x | 1.11x |
Competitor Companies of SANION by Market Capitalization
Companies near Saniona AB in the global market cap rankings as of September 19, 2026. Review Saniona AB (SANION) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Saniona AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Saniona AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Saniona AB's market cap moved from $234.05 Million to $ 148.54 Million, with a yearly change of -1.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr148.54 Million | -52.83% |
| 2025 | Skr314.91 Million | +163.68% |
| 2024 | Skr119.43 Million | +100.50% |
| 2023 | Skr59.57 Million | +30.83% |
| 2022 | Skr45.53 Million | -65.37% |
| 2021 | Skr131.46 Million | -57.04% |
| 2020 | Skr306.00 Million | -19.84% |
| 2019 | Skr381.75 Million | -17.43% |
| 2018 | Skr462.31 Million | +4.23% |
| 2017 | Skr443.53 Million | -25.12% |
| 2016 | Skr592.34 Million | +153.09% |
| 2015 | Skr234.05 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Saniona AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $148.54 Million USD |
| MoneyControl | $148.54 Million USD |
| MarketWatch | $148.54 Million USD |
| marketcap.company | $148.54 Million USD |
| Reuters | $148.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more